GTHX G1 Therapeutics Inc.

22.09
-1.55  -7%
Previous Close 23.64
Open 23.76
Price To Book 2.9
Market Cap 830,175,600
Shares 37,581,512
Volume 322,849
Short Ratio
Av. Daily Volume 327,569
Stock charts supplied by TradingView

NewsSee all news

  1. Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer

    SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate

  2. G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will

  3. G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

    RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical

  4. G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will

  5. G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

OS update 2H 2020.
Trilaciclib
Triple-negative breast cancer
Phase 1/2 poster at ESMO September 28, 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 2 data presented at ESMO September 29, 2019.
Trilaciclib plus Tecentriq
First-line small-cell lung cancer
Phase 1b data due at SABCS December 11, 2019 noted median PFS of 15 months. Further update due 2020.
Lerociclib (G1T38) plus Faslodex
ER+ breast cancer
Rolling NDA filing to be completed 2Q 2020.
Trilaciclib
Second/third-line small-cell lung cancer
Phase 2 patient-reported outcomes (PRO) presented at MASCC meeting June 21, 2019.
Trilaciclib
Small-cell lung cancer
Phase 1/2 data update and Phase 3 trial initiation due 2H 2020.
G1T48
ER+, HER2- breast cancer

Latest News

  1. Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer

    SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate

  2. G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will

  3. G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

    RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical

  4. G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will

  5. G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will

  6. G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update

    Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO Management to host webcast and conference call

  7. G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

    -- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:

  8. G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

    -- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients

  9. G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress

    -  Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for late-breaking oral

  10. G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a